InfuCare Rx Completes Recapitalization with a New Strategic
Capital Partner
As we enter our next chapter, we are focused on scaling our
impact and delivering best-in-class services that outperform
national competitors.”
– Deven Patel, Founder and CEO of InfuCare Rx
FAIRFIELD, NJ, UNITED STATES, November 7, 2025 /EINPresswire.com/
— InfuCare Rx, one of the nation’s largest independent providers
of specialty infusion services, announced it has completed a
recapitalization of the business through a strategic founder-led
equity buyback. Guggenheim Investments served as the strategic
capital partner on behalf of certain of its clients for this
milestone transaction. This transaction underscores InfuCare Rx
management’s long-term commitment to the firm’s vision and
values.
Founded in 2014, InfuCare has become one of the nation’s largest
privately held independent providers of specialty infusion
therapies at home as well as alternate sites of care. InfuCare Rx
is committed to providing comprehensive and unparalleled clinical
therapy management services to patients with complex conditions.
The company focuses on treating rare and chronic conditions such
as Myasthenia Gravis, CIDP, Crohn’s, Rheumatoid Arthritis,
Primary immunodeficiency disorders, and bleeding disorders.
InfuCare operates three segments: Immunoglobulin (“IG”) Therapy,
Specialty Infusion, and Bleeding Disorders, servicing over 14,000
patients across all 50 states with approximately 800 employees.
Deven Patel, founder and CEO of InfuCare Rx, said, “We want to
extend our appreciation to One Equity Partners for their
partnership and support over the years in helping us scale
operations, strengthen our infrastructure, and build a resilient
business. As we enter our next chapter, we are focused on scaling
our impact and delivering best-in-class services that outperform
national competitors. We are grateful to partner with Guggenheim
on the exciting new chapter for InfuCare.”
“We are excited to support Deven Patel and the InfuCare Rx team
in its next phase as a wholly founder-owned independent specialty
infusion provider that can benefit from Guggenheim Investments’
strategic and capital support for continued growth,” said Michael
Galzerano, Director at Guggenheim Investments.
About InfuCare Rx(r)
InfuCare Rx is a leading nationwide specialty infusion therapy
services provider for patients with complex conditions.
Accredited by URAC and ACHC, InfuCare Rx provides a consistent,
coordinated infusion experience for patients in the convenience
of their home or alternate care setting. Our dedicated team of
pharmacists, nurses, and other trained professionals strives to
provide optimal patient outcomes through cost-effective,
patient-centric services.
About Guggenheim Investments
Guggenheim Investments is a leading global asset manager with
more than $357 billion in total assets across fixed income,
equity, and alternative investments*. The firm serves a diverse
client base, including institutions, financial intermediaries,
and private clients.
Providers of infusion therapy specialize in select therapies
tailored for patients. A growing trend is the implementation of
Centers of Excellence to offer specialized medications. InfuCare
Rx, one of the nation’s largest independent providers of
specialty infusion services, announced
<https://www.einpresswire.com/article/865084253/infucare-rx-compl
etes-recapitalization-with-a-new-strategic-capital-partner> it
has completed a recapitalization of the business through a
strategic founder-led equity buyback. Guggenheim Investments
served as the strategic capital partner on behalf of certain of
its clients for this milestone transaction.
Founded in 2014, InfuCare Rx’s data-driven Centers of Excellence
offer patients high-touch personalized care in the treatment of
acute and chronic conditions. The company focuses on treating
rare and chronic conditions such as Myasthenia Gravis, CIDP,
Crohn’s, Rheumatoid Arthritis, Primary immunodeficiency
disorders, and bleeding disorders.
InfuCare Rx operates three segments: Immunoglobulin Therapy,
Specialty Infusion, and Bleeding Disorders, servicing over 14,000
patients across all 50 states with approximately 800 employees.
The M&A market for healthcare companies continues to build on STRATEGIC opportunities and a fragmented market. Consolidations along with unprecedented demand are driving scale across the continuum of care. The strategic corporate buyers and private equity investors remain committed to acquiring strong businesses that are well prepared for a transaction. Across the continuum of care, these buyers and investors are looking for well established, profitable businesses and offering prime valuations and options for management.
Do you know the current market value of your business? We do! We are here to help you plan, prepare, explore and succeed in executing your strategic options.
Contact Paragon Ventures for more information.
800-719-1555
